Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:EMBCNASDAQ:IRMDNASDAQ:NYXH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$15.65-2.6%$17.78$5.55▼$21.00$693.98M1423,072 shs317,615 shsEMBCEmbecta$11.91+0.1%$13.49$10.00▼$21.48$692.38M1.23453,195 shs513,062 shsIRMDIradimed$51.96-2.0%$53.57$40.18▼$63.29$660.67M0.8244,584 shs31,841 shsNYXHNyxoah$5.98$9.12$5.55▼$12.21$203.68M1.5563,226 shs76,186 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen-2.55%-1.63%-9.28%-16.44%+122.62%EMBCEmbecta+0.08%+3.57%-9.43%-38.58%+12.46%IRMDIradimed-2.02%+6.76%-0.93%-11.60%+27.10%NYXHNyxoah0.00%-1.32%-43.10%-40.50%-32.81%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.9592 of 5 stars3.53.00.00.03.52.50.6EMBCEmbecta4.5341 of 5 stars3.23.03.30.03.32.53.8IRMDIradimed4.8739 of 5 stars3.54.02.54.43.03.31.9NYXHNyxoah2.0579 of 5 stars3.53.00.00.01.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.6044.41% UpsideEMBCEmbecta 2.33Hold$20.3370.72% UpsideIRMDIradimed 3.00Buy$72.0038.57% UpsideNYXHNyxoah 3.00Buy$14.75146.66% UpsideCurrent Analyst Ratings BreakdownLatest NYXH, AXGN, EMBC, and IRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/8/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/26/2025NYXHNyxoahHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $15.003/17/2025AXGNAxoGenLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/14/2025NYXHNyxoahStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.003/5/2025AXGNAxoGenCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$24.00 ➝ $24.002/26/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.002/14/2025IRMDIradimedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $72.002/3/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $22.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M3.70N/AN/A$2.22 per share7.05EMBCEmbecta$1.11B0.63$2.76 per share4.32($13.23) per share-0.90IRMDIradimed$73.24M9.02$1.30 per share40.12$5.66 per share9.18NYXHNyxoah$4.52M45.05N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$21.72M-$0.22N/AN/AN/A-7.91%-14.91%-7.49%5/1/2025 (Estimated)EMBCEmbecta$78.30M$1.0011.913.880.785.25%-19.22%11.92%5/8/2025 (Estimated)IRMDIradimed$19.23M$1.5034.6425.98N/A26.26%24.12%21.20%5/1/2025 (Estimated)NYXHNyxoah-$46.77M-$1.95N/AN/AN/A-1,043.93%-51.68%-40.11%5/13/2025 (Estimated)Latest NYXH, AXGN, EMBC, and IRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NYXHNyxoah-$0.49N/AN/AN/A$1.64 millionN/A5/8/2025Q2 2025EMBCEmbecta$0.66N/AN/AN/A$261.77 millionN/A5/1/2025Q1 2025AXGNAxoGen-$0.01N/AN/AN/A$48.35 millionN/A5/1/2025Q1 2025IRMDIradimed$0.43N/AN/AN/A$19.33 millionN/A3/13/2025Q4 2024NYXHNyxoah-$0.46-$0.49-$0.03-$0.49$2.02 million$1.35 million2/13/2025Q4 2024IRMDIradimed$0.45$0.40-$0.05$0.40$19.09 million$19.39 million2/6/2025Q1 2025EMBCEmbecta$0.45$0.65+$0.20$1.30$256.08 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/AEMBCEmbecta$0.605.04%N/A60.00%N/AIRMDIradimed$0.681.31%N/A45.33%N/ANYXHNyxoahN/AN/AN/AN/AN/ALatest NYXH, AXGN, EMBC, and IRMD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/6/2025EMBCEmbectaquarterly$0.153.5%2/28/20252/28/20253/14/20252/6/2025IRMDIradimedquarterly$0.171.1%2/24/20252/24/20253/5/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.673.742.47EMBCEmbectaN/A2.241.67IRMDIradimedN/A9.217.82NYXHNyxoah0.215.284.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%EMBCEmbecta93.83%IRMDIradimed92.34%NYXHNyxoahN/AInsider OwnershipCompanyInsider OwnershipAXGNAxoGen7.00%EMBCEmbecta0.42%IRMDIradimed37.10%NYXHNyxoah17.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45044.34 million40.93 millionOptionableEMBCEmbecta1,90058.13 million57.89 millionOptionableIRMDIradimed11012.72 million7.97 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionableNYXH, AXGN, EMBC, and IRMD HeadlinesRecent News About These CompaniesConditional Issuance of SharesApril 16 at 2:00 AM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 15 at 1:30 PM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nyxoah S.A. (NYXH) and Encourages Investors to Learn More About the InvestigationApril 15 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 14 at 6:19 PM | prnewswire.comNyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the InvestigationApril 14 at 10:00 AM | accessnewswire.comBronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to ConnectApril 13 at 10:43 AM | markets.businessinsider.comBronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Investors to ConnectApril 13 at 10:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 12, 2025 | gurufocus.comBronstein, Gewirtz & Grossman, LLC Is Investigating Nyxoah S.A. (NYXH) And Encourages Stockholders to ConnectApril 11, 2025 | accessnewswire.comKepler Capital Sticks to Its Buy Rating for Nyxoah (NYXH)April 10, 2025 | markets.businessinsider.comNyxoah S.A. (NYXH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the InvestigationApril 10, 2025 | accessnewswire.comNyxoah (NASDAQ:NYXH) Given "Buy" Rating at HC WainwrightApril 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 9, 2025 | accessnewswire.comNyxoah anticipates FDA approval for Genio system in Q2April 8, 2025 | markets.businessinsider.comBronstein, Gewirtz & Grossman, LLC Encourages Nyxoah S.A. (NYXH) Investors to Inquire about Securities InvestigationApril 8, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 8, 2025 | prnewswire.comNyxoah Provides Update on FDA Approvable Letter for Genio SystemApril 8, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nyxoah S.A. (NYXH) And Encourages Investors to Reach OutApril 7, 2025 | accessnewswire.comNYXH Investors Have Opportunity to Join Nyxoah S.A. Fraud Investigation with the Schall Law FirmApril 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 7, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXHApril 6, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNYXH, AXGN, EMBC, and IRMD Company DescriptionsAxoGen NASDAQ:AXGN$15.65 -0.41 (-2.55%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$15.76 +0.11 (+0.67%) As of 05:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Embecta NASDAQ:EMBC$11.91 +0.01 (+0.08%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$12.38 +0.47 (+3.95%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Iradimed NASDAQ:IRMD$51.96 -1.07 (-2.02%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$51.88 -0.08 (-0.15%) As of 05:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.Nyxoah NASDAQ:NYXH$5.98 0.00 (0.00%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$5.98 +0.00 (+0.07%) As of 06:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
